Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2018-04-20

FDA Approved: AMLODIPINE BESYLATE — Supplemental Application (Cipla USA Inc.)

View source ↗

Summary

FDA approved Cipla USA Inc.'s supplemental application for amlodipine besylate under ANDA077073.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Amlodipine besylate (amlodipine besylate)

Snippet

SUPPL AP for AMLODIPINE BESYLATE (AMLODIPINE BESYLATE)